RxDoctor Payments Data

Eric Lara

Family · Munster, INNPI 1245944198

Payments from drug & device makers

$7,974in general payments, 2019–2025

Across 363 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$825
  • AstraZeneca$691
  • Otsuka America Pharmaceutical, Inc.$628
  • Novo Nordisk$501
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$433
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,974 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$47,269
Medicare patients
126
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$19,821
JardianceEmpagliflozin14$15,792
Levothyroxine Sodium86$1,132
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$967
Albuterol Sulfate HfaAlbuterol Sulfate21$830
Fenofibrate19$558
Metoprolol Succinate40$482
Bumetanide12$445
Tamsulosin Hcl47$428
Atorvastatin Calcium60$425
Gabapentin33$375
Allopurinol27$341
Amlodipine Besylate68$334
Alprazolam54$316
Metoprolol Tartrate33$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$501$19,82124 claims
Boehringer IngelheimJardiance$116$15,79214 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$1,13286 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →